Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Go back to Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss| Regeneron (NASDAQ: REGN) | Delayed: 804.03 -3.45 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $807.48 | 52 Week High | $592.36 | |||
| Open | $806.74 | 52 Week Low | $325.35 | |||
| Day High | $813.86 | P/E | 211.03 | |||
| Day Low | $800.24 | EPS | $3.81 | |||
| Volume | 225,313 | |||||



